| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.
|
Nat Genet
|
2013
|
5.58
|
|
2
|
Prediction of erectile function following treatment for prostate cancer.
|
JAMA
|
2011
|
3.92
|
|
3
|
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.
|
Eur Urol
|
2013
|
3.41
|
|
4
|
Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program.
|
J Endourol
|
2014
|
2.78
|
|
5
|
Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.
|
Eur Urol
|
2013
|
2.74
|
|
6
|
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21.
|
Nat Genet
|
2011
|
2.70
|
|
7
|
Effect of reclassification on the incidence of benign and malignant renal tumors.
|
J Urol
|
2009
|
2.67
|
|
8
|
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer.
|
Nat Genet
|
2008
|
2.45
|
|
9
|
Castration-resistant prostate cancer: AUA Guideline.
|
J Urol
|
2013
|
2.36
|
|
10
|
Comparison of hand assisted and standard laparoscopic radical nephroureterectomy for the management of localized transitional cell carcinoma.
|
J Urol
|
2002
|
2.23
|
|
11
|
Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.
|
Carcinogenesis
|
2009
|
2.17
|
|
12
|
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
|
J Nucl Med
|
2003
|
2.16
|
|
13
|
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care.
|
Eur Urol
|
2012
|
2.05
|
|
14
|
Readmissions after major urologic cancer surgery.
|
Can J Urol
|
2014
|
2.05
|
|
15
|
To biopsy or not to biopsy: minimizing the risk of prostate needle biopsy.
|
J Urol
|
2012
|
2.01
|
|
16
|
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample.
|
Eur Urol
|
2012
|
1.86
|
|
17
|
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression.
|
Hum Mol Genet
|
2013
|
1.78
|
|
18
|
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era.
|
J Clin Oncol
|
2014
|
1.74
|
|
19
|
SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer.
|
Hum Mol Genet
|
2008
|
1.62
|
|
20
|
Validation of genome-wide prostate cancer associations in men of African descent.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.62
|
|
21
|
The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence.
|
Am J Surg Pathol
|
2010
|
1.61
|
|
22
|
11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction.
|
J Nucl Med
|
2013
|
1.60
|
|
23
|
Prostate cancer risk associated loci in African Americans.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.49
|
|
24
|
Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis.
|
BJU Int
|
2015
|
1.47
|
|
25
|
Prognostic impact of comorbidity in patients with bladder cancer.
|
Eur Urol
|
2007
|
1.45
|
|
26
|
Ability of linear length of positive margin in radical prostatectomy specimens to predict biochemical recurrence.
|
Urology
|
2011
|
1.43
|
|
27
|
Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma.
|
J Urol
|
2010
|
1.39
|
|
28
|
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent.
|
Prostate Cancer
|
2013
|
1.37
|
|
29
|
Transitional cell carcinoma of the renal pelvis associated with hypercalcemia in a patient with autosomal dominant polycystic kidney disease.
|
Urology
|
2004
|
1.26
|
|
30
|
The 2011-2016 Transdisciplinary Research on Energetics and Cancer (TREC) initiative: rationale and design.
|
Cancer Causes Control
|
2013
|
1.26
|
|
31
|
Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.
|
Urology
|
2007
|
1.18
|
|
32
|
Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans.
|
Magn Reson Med
|
2009
|
1.17
|
|
33
|
Surgical treatment of renal neoplasia: evolving toward a laparoscopic standard of care.
|
Urology
|
2003
|
1.17
|
|
34
|
Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study.
|
Radiology
|
2014
|
1.13
|
|
35
|
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer.
|
BJU Int
|
2008
|
1.07
|
|
36
|
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.
|
Cancer
|
2013
|
1.05
|
|
37
|
Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity.
|
J Urol
|
2009
|
1.03
|
|
38
|
Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.
|
Clin Cancer Res
|
2011
|
1.01
|
|
39
|
Ureteral injury in laparoscopic gynecologic surgery.
|
Rev Obstet Gynecol
|
2012
|
1.01
|
|
40
|
The distribution of histological subtypes of renal tumors by decade of life using the 2004 WHO classification.
|
J Urol
|
2008
|
0.99
|
|
41
|
Prostate cancer: screening, diagnosis and management in 2007.
|
Mo Med
|
2007
|
0.97
|
|
42
|
The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update.
|
BJU Int
|
2015
|
0.97
|
|
43
|
Generalizability of established prostate cancer risk variants in men of African ancestry.
|
Int J Cancer
|
2014
|
0.96
|
|
44
|
Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma.
|
Urology
|
2008
|
0.95
|
|
45
|
The role of systemic cytotoxic therapy for prostate cancer.
|
BJU Int
|
2008
|
0.94
|
|
46
|
Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC).
|
BJU Int
|
2013
|
0.91
|
|
47
|
Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma.
|
Prostate
|
2006
|
0.90
|
|
48
|
Rapid resolution of carbon dioxide pneumothorax (capno-thorax) resulting from diaphragmatic injury during laparoscopic nephrectomy.
|
J Urol
|
2002
|
0.90
|
|
49
|
Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium.
|
Cancer Res
|
2013
|
0.89
|
|
50
|
The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection.
|
Urol Oncol
|
2009
|
0.88
|
|
51
|
Management of the postpubertal patient with cryptorchidism: an updated analysis.
|
J Urol
|
2002
|
0.87
|
|
52
|
Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.
|
J Urol
|
2012
|
0.87
|
|
53
|
Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
|
Cancer
|
2012
|
0.86
|
|
54
|
Targeting the androgen receptor--theory and practice.
|
Urology
|
2011
|
0.85
|
|
55
|
The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACS-NSQIP) 2005-2011.
|
World J Surg
|
2015
|
0.84
|
|
56
|
Trends in nephron-sparing surgery for renal neoplasia.
|
Urology
|
2006
|
0.84
|
|
57
|
Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors.
|
Cancer
|
2002
|
0.83
|
|
58
|
High-risk localized prostate cancer: role of radical prostatectomy.
|
Curr Opin Urol
|
2010
|
0.83
|
|
59
|
Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).
|
BJU Int
|
2014
|
0.82
|
|
60
|
BCAN Think Tank session 3: Prevention of bladder cancer.
|
Urol Oncol
|
2010
|
0.81
|
|
61
|
Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer.
|
Urol Oncol
|
2011
|
0.80
|
|
62
|
Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma.
|
Prostate
|
2010
|
0.80
|
|
63
|
Laparoscopic retroperitoneal lymph node dissection for low-stage cancer: a Washington University update.
|
J Endourol
|
2011
|
0.80
|
|
64
|
Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.79
|
|
65
|
Local treatment of high risk prostate cancer: Role of surgery and radiation therapy.
|
Cancer
|
2014
|
0.79
|
|
66
|
Foamy gland adenocarcinoma of the prostate: incidence, Gleason grade, and early clinical outcome.
|
Hum Pathol
|
2012
|
0.79
|
|
67
|
Minimally invasive approaches to localized prostate carcinoma.
|
Hematol Oncol Clin North Am
|
2006
|
0.79
|
|
68
|
Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures: Results From the National Surgical Quality Improvement Program.
|
Ann Surg
|
2015
|
0.79
|
|
69
|
Preventable mortality after common urological surgery: failing to rescue?
|
BJU Int
|
2014
|
0.79
|
|
70
|
Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC).
|
BJU Int
|
2014
|
0.79
|
|
71
|
Treat now or later: the dilemma of postoperative radiotherapy.
|
Eur Urol
|
2011
|
0.79
|
|
72
|
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
|
Br J Cancer
|
2016
|
0.78
|
|
73
|
Optimizing prostate biopsy techniques.
|
J Urol
|
2007
|
0.78
|
|
74
|
Percentage of high-grade carcinoma as a prognostic indicator in patients with renal cell carcinoma.
|
Cancer
|
2008
|
0.78
|
|
75
|
Indications and practice with androgen deprivation therapy.
|
Urology
|
2011
|
0.77
|
|
76
|
Intravesical bacille Calmette-Guérin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy.
|
J Am Coll Surg
|
2009
|
0.77
|
|
77
|
Positive margin during partial nephrectomy: does cancer remain in the renal remnant?
|
Urology
|
2011
|
0.77
|
|
78
|
Early detection, PSA screening, and management of overdiagnosis.
|
Hematol Oncol Clin North Am
|
2013
|
0.76
|
|
79
|
The use and abuse of data: nomograms and talking to patients about clinical medicine.
|
Urol Oncol
|
2007
|
0.76
|
|
80
|
Chronic kidney disease and perioperative outcomes in urological oncological surgery.
|
Int J Urol
|
2014
|
0.76
|
|
81
|
Words of wisdom. Re: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
|
Eur Urol
|
2009
|
0.75
|
|
82
|
Words of wisdom. Re: Intermittent androgen suppression for rising PSA level after radiotherapy.
|
Eur Urol
|
2013
|
0.75
|
|
83
|
Androgen deprivation therapy for localized and nonmetastatic prostate cancer: too much of a good thing?
|
Eur Urol
|
2012
|
0.75
|
|
84
|
Words of wisdom. Re: EPCA-2: a highly specific serum marker for prostate cancer.
|
Eur Urol
|
2008
|
0.75
|
|
85
|
Editorial comment.
|
J Urol
|
2009
|
0.75
|
|
86
|
Editorial for "Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50".
|
Cancer
|
2010
|
0.75
|
|
87
|
Counterpoint: Prostate carcinoma treatment for the young patient--The case for radical prostatectomy.
|
Brachytherapy
|
2010
|
0.75
|
|
88
|
Editorial comment.
|
J Urol
|
2009
|
0.75
|
|
89
|
Words of wisdom. Re: active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
|
Eur Urol
|
2011
|
0.75
|
|
90
|
Editorial comment.
|
J Urol
|
2013
|
0.75
|
|
91
|
Adverse pathologic characteristics in the small renal mass: implications for active surveillance.
|
Can J Urol
|
2017
|
0.75
|
|
92
|
Parenchymal imaging adds diagnostic utility in evaluating haematuria.
|
BJU Int
|
2005
|
0.75
|
|
93
|
Highlights of the 2010 SUO Annual Meeting.
|
Urol Oncol
|
2011
|
0.75
|
|
94
|
The Second Joint Meeting of American Urological Association (AUA)/Japanese Urological Association (JUA) International Program on the 102nd Annual Meeting of American Urological Association at Anaheim 2007.
|
Int J Urol
|
2007
|
0.75
|
|
95
|
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
|
Can J Urol
|
2015
|
0.75
|